Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
Sabbagh
Marwan N
MN
The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ, USA. Marwan.Sabbagh@sunhealth.org
D000544:Alzheimer Disease / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D000077265:Donepezil; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D015337:Multicenter Studies as Topic; D010880:Piperidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
D000924:Anticholesteremic Agents; D002800:Cholinesterase Inhibitors; D006538:Heptanoic Acids; D007189:Indans; D010880:Piperidines; D011758:Pyrroles; D000077265:Donepezil; D000069059:Atorvastatin